European Endocrinology最新文献_第9页

Mind-Body Interactions and Mindfulness Meditation in Diabetes. 糖尿病的身心互动和正念冥想。

European Endocrinology Pub Date : 2018-04-01 Epub Date: 2018-04-18 DOI: 10.17925/EE.2018.14.1.35

Gagan Priya, Sanjay Kalra

{"title":"Mind-Body Interactions and Mindfulness Meditation in Diabetes.","authors":"Gagan Priya, Sanjay Kalra","doi":"10.17925/EE.2018.14.1.35","DOIUrl":"https://doi.org/10.17925/EE.2018.14.1.35","url":null,"abstract":"Diabetes is associated with significant psychological distress. It is, therefore, important to ensure the physical and emotional as well as psychosocial wellbeing of individuals living with diabetes. Meditation-based strategies have been evaluated for their complementary role in several chronic disorders including depression, anxiety, obesity, hypertension, cardiovascular disease and diabetes. The practice of meditation is associated with reduction in stress and negative emotions and improvements in patient attitude, health-related behaviour and coping skills. There is increased parasympathetic activity with reduction in sympathetic vascular tone, stress hormones and inflammatory markers. Additionally, several studies evaluated the role of mindfulness-based stress reduction in diabetic individuals and demonstrated modest improvements in body weight, glycaemic control and blood pressure. Thus, mindfulness meditation-based intervention can lead to improvements across all domains of holistic care - biological, psychological and social. Though most of these studies have been of short duration and included small numbers of patients, meditation strategies can be useful adjunctive techniques to lifestyle modification and pharmacological management of diabetes and help improve patient wellbeing.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"14 1","pages":"35-41"},"PeriodicalIF":0.0,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.17925/EE.2018.14.1.35","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36240215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

The GlucoCoper - a Tool for the Assessment of Coping Mechanisms. 葡萄糖-一个评估应对机制的工具。

European Endocrinology Pub Date : 2018-04-01 Epub Date: 2018-04-18 DOI: 10.17925/EE.2018.14.1.52

Sanjay Kalra, Yatan Pal Singh Balhara, Komal Verma, Bharti Kalra

引用次数: 3

¹⁸F-Fluorocholine-Positron Emission Tomography/Computerised Tomography is Useful in Localising ^99mTc-Sesta-methoxyisobutylisonitrile-Negative Parathyroid Cyst Causing Normocalcemic Primary Hyperparathyroidism. 18f -氟胆碱-正电子发射断层扫描/计算机断层扫描有助于定位99mtc - sesta -甲氧基异丁基异硝基-阴性甲状旁腺囊肿引起的正常钙血症原发性甲状旁腺功能亢进。

European Endocrinology Pub Date : 2018-04-01 Epub Date: 2018-04-18 DOI: 10.17925/EE.2018.14.1.56

Deep Dutta, Pradeep Kumar Gupta, Meha Sharma, Nishikant Avinash Damble, Renu Madan, Shruti Dogra

{"title":"18F-Fluorocholine-Positron Emission Tomography/Computerised Tomography is Useful in Localising 99mTc-Sesta-methoxyisobutylisonitrile-Negative Parathyroid Cyst Causing Normocalcemic Primary Hyperparathyroidism.","authors":"Deep Dutta, Pradeep Kumar Gupta, Meha Sharma, Nishikant Avinash Damble, Renu Madan, Shruti Dogra","doi":"10.17925/EE.2018.14.1.56","DOIUrl":"https://doi.org/10.17925/EE.2018.14.1.56","url":null,"abstract":"Parathyroid cysts are extremely rare and are rarely associated with primary hyperparathyroidism (PHPT), which are difficult to localise, as they are 99mTc-sesta-methoxyisobutylisonitrile (sestaMIBI) negative. We report for the first time the utility of 18F-fluorocholinepositron emission tomography/computerised tomography (PC-PET/CT) in localising parathyroid cyst causing normocalcemic PHPT. A 76-year-old lady with progressively worsening osteoporosis from 2014-2017 (in spite of annual zolendronic acid infusions, daily calcium and vitamin-D supplementation) with persistently normal serum calcium and vitamin D, but elevated parathyroid hormone, had normal sestaMIBI scans of the neck on multiple occasions. FC-PET/CT finally revealed soft tissue uptake, suggestive of right superior parathyroid adenoma/ hyperplasia. Surgical removal of the culprit lesion resulted in resolution of hyperparathyroidism, histopathologic evaluation of which revealed a cystic lesion lined by chief cell variant parathyroid cells without any nuclear atypia, capsular or vascular invasion. FC-PET/CT is useful in localising culprit parathyroid lesions, especially when they are sestaMIBI negative. PC-PET/CT is useful in localising parathyroid hyperplasia and ectopic parathyroids, which are frequently missed by sestaMIBI. There is an urgent need for comparative studies between sestaMIBI and FC-PET/CT in PHPT. We report for the first time the usefulness of FC-PET/CT in localising sestaMIBI-negative functional parathyroid cyst causing normocalcemic PHPT.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"14 1","pages":"56-58"},"PeriodicalIF":0.0,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.17925/EE.2018.14.1.56","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36240219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

A Retrospective Review of the Clinical Characteristics and Blood Glucose Data from Cellnovo System Users using Data Collected from the Cellnovo Online Platform. 使用Cellnovo在线平台收集的数据对Cellnovo系统用户的临床特征和血糖数据进行回顾性分析。

European Endocrinology Pub Date : 2018-04-01 Epub Date: 2018-04-18 DOI: 10.17925/EE.2018.14.1.30

Olivia Hautier-Suply, Yasmin Friedmann, Julian Shapley

{"title":"A Retrospective Review of the Clinical Characteristics and Blood Glucose Data from Cellnovo System Users using Data Collected from the Cellnovo Online Platform.","authors":"Olivia Hautier-Suply, Yasmin Friedmann, Julian Shapley","doi":"10.17925/EE.2018.14.1.30","DOIUrl":"https://doi.org/10.17925/EE.2018.14.1.30","url":null,"abstract":"Technological advances have led to innovative insulin delivery systems for patients with type 1 diabetes mellitus. In particular, the combination of miniature engineering and software algorithms contained in continuous subcutaneous insulin infusion (CSII) system pumps provide the user and the healthcare practitioner with an opportunity to review and adjust blood glucose (BG) levels according to system feedback, and to modify or programme their regimen according to their needs. While CSII pumps record a number of data parameters such as BG level, carbohydrate intake, activity and insulin delivered, these data are generally 'locked in' and can only be accessed by uploading to a cloud-based system, thus information is not contemporaneous. The Cellnovo Diabetes Management System (Cellnovo, Bridgend, UK) allows data to be transmitted securely and wirelessly in real time to a secure server, which is then retrieved by an online platform, the Cellnovo Online platform, enabling continuous access by the user and by clinicians. In this article, the authors describe a retrospective review of the patient data automatically uploaded to the Cellnovo Online platform. Baseline clinical and demographic characteristics collected at the start of pump therapy are shown for all patients, and BG data from a sub-cohort of patients who have been using the system for at least 6 months and who take and record an average of three BG level tests per day are presented to demonstrate glycaemic data over time.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"14 1","pages":"30-34"},"PeriodicalIF":0.0,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/08/euendo-14-30.PMC5954592.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36240214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data. 使用钠-葡萄糖共转运蛋白2抑制剂对心血管的益处-真实世界数据

European Endocrinology Pub Date : 2018-04-01 Epub Date: 2018-04-18 DOI: 10.17925/EE.2018.14.1.17

Baptist Gallwitz

{"title":"The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.","authors":"Baptist Gallwitz","doi":"10.17925/EE.2018.14.1.17","DOIUrl":"https://doi.org/10.17925/EE.2018.14.1.17","url":null,"abstract":"Type 2 diabetes (T2D) is associated with numerous comorbidities that significantly reduce quality of life, increase mortality and complicate treatment decisions. In a recent cardiovascular outcomes trial, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME), the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin was shown to reduce cardiovascular (CV) mortality and heart failure in high-risk patients with T2D with a previous CV event or with established CV disease (CVD). Recently published data from the Canagliflozin Cardiovascular Assessment Study (CANVAS-PROGRAM) study suggested that the cardiovascular benefits of empagliflozin are also seen with the SGLT2-inhibitor canagliflozin, indicating a class effect of SGLT2 inhibitors. Evidence for a class effect has also been shown by meta-analyses and real-world studies, including the Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL) and The Health Improvement Network (THIN) databases. These findings also suggest the results of EMPA-REG OUTCOME can be applied to patients with T2D with a broader CV risk profile, including people at low risk of CVD.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"14 1","pages":"17-23"},"PeriodicalIF":0.0,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/98/euendo-14-17.PMC5954590.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36240211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 28

Selecting the Appropriate Continuous Glucose Monitoring System - a Practical Approach. 选择合适的连续血糖监测系统-一种实用的方法。

European Endocrinology Pub Date : 2018-04-01 Epub Date: 2018-04-18 DOI: 10.17925/EE.2018.14.1.24

Peter Adolfsson, Christopher G Parkin, Andreas Thomas, Lars G Krinelke

引用次数: 39

Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment. 雷尼单抗治疗糖尿病黄斑水肿-雷尼单抗0.5 mg PRN与激光治疗的获益-风险分析

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.91

Focke Ziemssen, Alan Cruess, Cornelia Dunger-Baldauf, Philippe Margaron, Howard Snow, William David Strain

{"title":"Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment.","authors":"Focke Ziemssen, Alan Cruess, Cornelia Dunger-Baldauf, Philippe Margaron, Howard Snow, William David Strain","doi":"10.17925/EE.2017.13.02.91","DOIUrl":"https://doi.org/10.17925/EE.2017.13.02.91","url":null,"abstract":"Introduction: The structured Benefit-risk Action Team (BRAT) approach aims to assist healthcare decision makers in treatment assessments. We applied BRAT to compare the benefit-risk profile of ranibizumab 0.5 mg versus laser photocoagulation for the treatment of diabetic macular oedema (DMO).Methods: One-year data for the ranibizumab 0.5 mg pro re nata (PRN) and laser arms of the phase III trials RESPOND (NCT01135914; n=220), RESTORE (NCT00687804; n=345), and REVEAL (NCT00989989; n=396) were included in the analysis. The benefit measures included ≥10 letters gain/avoidance of loss in best-corrected visual acuity (BCVA), achieving central retinal thickness (CRT) <275 μm, and 25-item Visual Function Questionnaire (VFQ-25) outcomes. The risks measures included endophthalmitis, intraocular pressure increase, hypertension, proteinuria, arterial/venous thromboembolic events and deaths.Results: Ranibizumab treatment provided significant benefits compared with laser for ≥10 letter BCVA gain at month 12 (387/1,000 versus 152/1,000 patients), CRT <275 μm at 12 months (474/1,000 versus 348/1,000 patients), and improvement of ≥6.06 on the VFQ-25 near activities subscale (325/1,000 versus 245/1,000 patients). Results for the risk measures were similar for both treatments.Conclusions: Superior clinically relevant outcomes were observed with ranibizumab 0.5 mg PRN compared with laser without compromising on safety. This analysis further supports the positive benefit-risk profile of ranibizumab 0.5 mg PRN.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"13 2","pages":"91-98"},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/93/euendo-13-91.PMC5813472.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35989223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Type 2 Diabetes Decompensation as the Clinical Presentation of Thyroid Storm - Cause or Consequence? 2型糖尿病失代偿是甲状腺风暴的临床表现——原因还是后果?

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.99

Ana Margarida Monteiro, Cláudia Matta-Coelho, Vera Fernandes, Olinda Marques

{"title":"Type 2 Diabetes Decompensation as the Clinical Presentation of Thyroid Storm - Cause or Consequence?","authors":"Ana Margarida Monteiro, Cláudia Matta-Coelho, Vera Fernandes, Olinda Marques","doi":"10.17925/EE.2017.13.02.99","DOIUrl":"https://doi.org/10.17925/EE.2017.13.02.99","url":null,"abstract":"This case study aims to discuss the unusual forms of hyperthyroidism presentation, the nonspecific symptoms and precipitating events. A 70-year-old male was taken to the emergency department for hyperglycaemia, nausea, vomiting and altered mental status with a week of evolution. He had a past medical history of type 2 diabetes, hypertension and dyslipidemia. He had no history of any recent intercurrent illness or infection. At the emergency room, besides hyperglycaemia, ketonemia and slightly elevated C-reactive protein, the basic laboratory panel workup was normal, as was the head computed tomography. He was admitted for metabolic compensation and to study the altered neurological status. During hospitalisation, despite the good glycemic control, he had no improvements in neurological status. At day four of hospitalisation, thyrotoxicosis with thyroid storm criteria was diagnosed. He started on adequate treatment with complete clinical recovery. The associated morbidity and mortality of thyroid storm requires immediate recognition and treatment. Elderly patients are frequently misdiagnosed or diagnosed later due to fewer and less pronounced signs and symptoms.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"13 2","pages":"99-101"},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/49/euendo-13-99.PMC5813473.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35989224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Ten Years of Vildagliptin. 维格列汀的十年。

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.54

Stefano Del Prato

引用次数: 2

Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. 维达列汀的临床安全性和耐受性--来自随机试验、观察性研究和上市后监测的启示。

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.68

Chantal Mathieu, Plamen Kozlovski, Päivi M Paldánius, James E Foley, Vikas Modgill, Marc Evans, Carmen Serban

引用次数: 0